Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Trends in Pharmacological Sciences|June 16, 2015
Exploring the potential of adjunct therapy in tuberculosisGeetha Vani Rayasam, Tanjore S BalganeshExpert Opinion on Therapeutic Targets|December 12, 2013
MmpL3 a potential new target for development of novel anti-tuberculosis drugsGeetha Vani RayasamScientific Reports|October 14, 2016
Development of a one-pot assay for screening and identification of Mur pathway inhibitors in Mycobacterium tuberculosisKandasamy Eniyan, Anuradha Kumar, Geetha Vani Rayasam, et al.Trends in Pharmacological Sciences|September 19, 2008
Rising standards for tuberculosis drug developmentTanjore S Balganesh, Pedro M Alzari, Stewart T ColeExpert Opinion on Therapeutic Targets|May 1, 2007
Fatty acid receptors as new therapeutic targets for diabetesGeetha Vani Rayasam, Vamshi Krishna Tulasi, Joseph Alex Davis, et al.British Journal of Pharmacology|April 16, 2009
Glycogen synthase kinase 3: more than a namesakeGeetha Vani Rayasam, Vamshi Krishna Tulasi, Reena Sodhi, et al.Phytotherapy Research : PTR|July 27, 2010
Identification of berberine as a novel agonist of fatty acid receptor GPR40Geetha Vani Rayasam, Vamshi Krishna Tulasi, Sindhuja Sundaram, et al.The EMBO Journal|June 14, 2003
NSD1 is essential for early post-implantation development and has a catalytically active SET domainGeetha Vani Rayasam, Olivia Wendling, Pierre-Olivier Angrand, et al.Journal of Biomolecular Screening|February 1, 2013
Assay development for identifying inhibitors of the mycobacterial FadD32 activitySégolène Galandrin, Valérie Guillet, Rajendra S Rane, et al.ACS Chemical Biology|December 28, 2012
Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosisPravin S Shirude, Prashanti Madhavapeddi, Julie A Tucker, et al.Pageof 2